Financial News
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles - (NewMediaWire) - November 3, 2021 - The Schall Law Firm, a national shareholder rights litigation
firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ:
BMRN) for violations of §§10(b) and 20(a) of the
Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the
U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities
between January 13, 2020, and September 3, 2021, inclusive (the ''Class Period''), are
encouraged to contact the firm before December 21, 2021.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of
the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067,
at 310-301-3335, to discuss your rights free of charge. You can also reach us
through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class, in this case, has not yet been
certified, and until certification occurs, you are not represented by an
attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made
false and misleading statements to the market. BioMarin overstated to investors
the safety of BMN 307, an AAV5 mediated gene therapy. In fact, BMN 307’s safety
profile made it likely that the FDA would place a clinical hold on the Phearless
Phase 1/2 study. Based on these facts, the Company’s public statements were
false and materially misleading throughout the class period. When the market
learned the truth about BioMarin, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors
around the world and specializes in securities class action lawsuits and
shareholder rights litigation.
This press release may be considered Attorney
Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
SOURCE:
The Schall Law Firm
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.